Net Profit Margin
since 2013
Calculation
IQVIA Holdings Inc., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income attributable to IQVIA Holdings Inc.1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | 7.57% | = | 100 | × | 1,091) | ÷ | 14,410) |
| Dec 31, 2021 | 6.96% | = | 100 | × | 966) | ÷ | 13,874) |
| Dec 31, 2020 | 2.46% | = | 100 | × | 279) | ÷ | 11,359) |
| Dec 31, 2019 | 1.72% | = | 100 | × | 191) | ÷ | 11,088) |
| Dec 31, 2018 | 2.49% | = | 100 | × | 259) | ÷ | 10,412) |
| Dec 31, 2017 | 13.44% | = | 100 | × | 1,309) | ÷ | 9,739) |
| Dec 31, 2016 | 1.67% | = | 100 | × | 115) | ÷ | 6,878) |
| Dec 31, 2015 | 6.75% | = | 100 | × | 387) | ÷ | 5,738) |
| Dec 31, 2014 | 6.53% | = | 100 | × | 356) | ÷ | 5,460) |
| Dec 31, 2013 | 4.44% | = | 100 | × | 227) | ÷ | 5,100) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$ in millions
The financial performance from 2013 to 2022 is characterized by a consistent and substantial expansion in top-line revenue, contrasted by significant volatility in net income and corresponding profit margins.
- Revenue Trajectory
- Revenues demonstrated an uninterrupted upward trend, increasing from US$ 5,100 million in 2013 to US$ 14,410 million in 2022. This steady growth indicates a sustained increase in the company's scale of operations over the ten-year period.
- Net Profit Margin Volatility
- The net profit margin experienced extreme fluctuations. An initial period of growth saw margins rise from 4.44% in 2013 to 6.75% in 2015, followed by a sharp contraction to 1.67% in 2016. A significant anomaly occurred in 2017, where the net profit margin reached a peak of 13.44%, driven by a surge in net income to US$ 1,309 million.
- Period of Margin Compression
- Following the 2017 peak, a period of notable margin compression was observed between 2018 and 2020. During these three years, net profit margins remained suppressed, fluctuating between a low of 1.72% in 2019 and a high of 2.49% in 2018, despite continued growth in total revenues.
- Recent Profitability Recovery
- A strong recovery in profitability began in 2021, with the net profit margin climbing to 6.96% and further increasing to 7.57% in 2022. This recovery is supported by a substantial increase in net income, which rose from US$ 279 million in 2020 to US$ 1,091 million by the end of 2022, suggesting improved operational efficiency or a change in the cost structure.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Comparison to Competitors
IQVIA Holdings Inc., net profit margin, long-term trends, comparison to competitors
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | 7.57% | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| Dec 31, 2021 | 6.96% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | 2.46% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 31, 2019 | 1.72% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 31, 2018 | 2.49% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 13.44% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 1.67% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 6.75% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 6.53% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 4.44% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2022 | 7.57% | 22.55% |
| Dec 31, 2021 | 6.96% | 23.38% |
| Dec 31, 2020 | 2.46% | 14.07% |
| Dec 31, 2019 | 1.72% | 23.22% |
| Dec 31, 2018 | 2.49% | 19.82% |
| Dec 31, 2017 | 13.44% | 13.06% |
| Dec 31, 2016 | 1.67% | 20.78% |
| Dec 31, 2015 | 6.75% | 21.17% |
| Dec 31, 2014 | 6.53% | 21.24% |
| Dec 31, 2013 | 4.44% | 21.99% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc., net profit margin, long-term trends, comparison to industry (health care)
| IQVIA Holdings Inc. | Health Care | |
|---|---|---|
| Dec 31, 2022 | 7.57% | 14.65% |
| Dec 31, 2021 | 6.96% | 15.24% |
| Dec 31, 2020 | 2.46% | 10.27% |
| Dec 31, 2019 | 1.72% | 14.56% |
| Dec 31, 2018 | 2.49% | 12.61% |
| Dec 31, 2017 | 13.44% | 9.26% |
| Dec 31, 2016 | 1.67% | 12.80% |
| Dec 31, 2015 | 6.75% | 13.94% |
| Dec 31, 2014 | 6.53% | 14.40% |
| Dec 31, 2013 | 4.44% | 15.04% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).